Whitehawk Therapeutics expands ADC pipeline with option for CPT113 in up to five new programs

Whitehawk Therapeutics, Inc.

Option agreement with Hangzhou DAC provides access to CPT113 for up to five internally developed ADC programs, including dual-payload variations.
DXC006 data from Hangzhou DAC accepted for oral presentation at ASCO; J&J disclosed an ADC using CPT113 at AACR.
PTK7-directed HWK-007 completed first dose cohort at 2 mg/kg, enrolling second cohort at 4 mg/kg; MUC16-directed HWK-016 enrolling first cohort at 2.5 mg/kg.
Phase 1 dose-escalation data for HWK-007 and HWK-016 expected in first half of 2027; IND for HWK-206 anticipated mid-2026.
Whitehawk retains global rights and full program control for new ADCs; anticipates IND submissions for multiple programs over next 12-24 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.